Galecto Inc Corporate Call-Topline data From the Company Phase 1b/2a GULLIVER-2 Trial for liver cirrhosis Transcript
Good morning, my name is Francesca and I will be your conference operator today. This time I'd like to welcome everyone to the Galecto GULLIVER-2 topline results conference call. (Operator Instructions) Please note this event is being recorded.
Jonathan Freve, you may begin your conference. Thank you.
Thank you, Francesca. Good morning, everyone, and welcome to the GULLIVER top-line results conference call. This morning we issued a press release announcing top-line results from our GULLIVER-2 trial, a Phase 1b/2a trial designed to assess the safety, tolerability, pharmacokinetics, and potential activity of GB1211 in patients with decompensated cirrhosis. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at www.galecto.com.
Before we get started, I would like to remind everyone that statements we make on this conference call include forward-looking statements,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |